2021

1. Egfr in cancer: Signaling mechanisms, drugs and acquired resistance

   Cancers, Vol. 13, Núm. 11

2. Host-dependent phenotypic resistance to EGFR tyrosine kinase inhibitors

   Cancer Research, Vol. 81, Núm. 14, pp. 3862-3875

3. TSHZ2 is an EGF-regulated tumor suppressor that binds to the cytokinesis regulator PRC1 and inhibits metastasis

   Science Signaling, Vol. 14, Núm. 688

4. Upfront admixing antibodies and EGFR inhibitors preempts sequential treatments in lung cancer models

   EMBO Molecular Medicine, Vol. 13, Núm. 4